Fate therapeutics announces presentation of ft819 proof-of-concept data for b cell-mediated autoimmune diseases at asgct annual meeting

Key therapeutic mechanisms of clinical activity for autoimmune diseases, including b cell depletion, tissue infiltration and immune reconstitution data, from phase 1 study of ft819 in relapsed / refractory b-cell malignancies to be highlighted
FATE Ratings Summary
FATE Quant Ranking